Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS6OV9
|
|||
| Drug Name |
THR-687
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 1 | [1] | |
| Diabetic retinopathy [ICD-11: 9B71.0; ICD-10: H36.0] | Phase 1 | [1] | ||
| Company |
Oxurion
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Integrin (ITG) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03666923) A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME). U.S. National Institutes of Health. | |||
| REF 2 | The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Exp Eye Res. 2019 Mar;180:43-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.